Name
Atypical chronic myeloid leukemia, BCR-ABL1-negative
ICD-O-1 Morphology
9863/3: Chronic myeloid leukemia, NOS
Effective
1978 - 1991
ICD-O-2 Morphology
9863/3: Chronic myeloid leukemia, NOS
Effective
1992 - 2000
ICD-O-3 Morphology
9876/3: Atypical chronic myeloid leukemia, BCR-ABL1 negative
Effective
2001 and later
Reportable
for cases diagnosed
1978 and later
Primary Site(s)
C421
Primary site must be bone marrow (C421)
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
Atypical CML BCR-ABL1 negative is a rare disease. The peripheral blood and bone marrow are always involved; spleen and hepatic involvement are common.
The physician will run tests to rule out BCR-ABL1 involvement.
For more information, see the NCI website: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq#section/_50
The physician will run tests to rule out BCR-ABL1 involvement.
For more information, see the NCI website: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq#section/_50
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Grade
Not Applicable
Module Rule
None
Alternate Names
aCML
Atypical chronic myeloid leukemia
Atypical chronic myeloid leukemia, BCR/ABL1-negative
Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative
Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1-)
Philadelphia chromosome (PH1) negative
Definition
aCML is a leukemic disorder with myelodysplastic as well as myeloproliferative features. It is characterized by principal involvement of the neutrophil series with leukocytosis comprised of immature and mature neutrophils that are dysplastic. Mutilineage dysplasia; however, is common and reflects the stem cell origin.
Definitive Diagnostic Methods
Bone marrow biopsy
Peripheral blood smear
Genetics Data
None
Immunophenotyping
None
Treatments
Chemotherapy
Hematologic Transplant and/or Endocrine Procedures
Immunotherapy
Transformations to
There are no known transformations
Transformations from
There are no known transformations
Same Primaries
Corresponding ICD-9 Codes
205.1 Chronic myeloid leukemia
Corresponding ICD-10 Codes
C92.1 Chronic myeloid leukemia
Corresponding ICD-10-CM Codes (U.S. only)
C92.2 Atypical chronic myeloid leukemia, BCR/ABL-negative (effective October 01, 2015)
Signs and Symptoms
Diagnostic Exams
Progression and Transformation
15-40% of patients evolve to acute myeloid leukemia
Epidemiology and Mortality
Age: 70-80 years median age
Sex: no male or female predominance
Survival: 14-29 months median survival time
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Myelodysplastic/myeloproliferative neoplasms
Pages: 87-89
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Myelodysplastic/myeloproliferative neoplasms
Pages: 87-89
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
National Cancer Institute
Section: General Information About Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN)
Pages: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq#section/_1
Section: General Information About Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN)
Pages: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq#section/_1